QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=2599C73EEFD551EF810AA9CC168CA553;jsessionid=406BED3138A959C6711723E40F23BD6F;jsessionid=97B328546C046CB9AB3C19533416E597;jsessionid=7AEC0FE61E17CC84AFFED31927242B84;jsessionid=34F20C16FF0CDB0FC74CBD5112A2003D;jsessionid=25DCD6F0813C3FFFE5201B0599091C30 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=2599C73EEFD551EF810AA9CC168CA553;jsessionid=406BED3138A959C6711723E40F23BD6F;jsessionid=97B328546C046CB9AB3C19533416E597;jsessionid=7AEC0FE61E17CC84AFFED31927242B84;jsessionid=34F20C16FF0CDB0FC74CBD5112A2003D;jsessionid=25DCD6F0813C3FFFE5201B0599091C30